Related Experiment Video
Updated: Jul 17, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
[Granulocyte-colony stimulating factor-producing multiple myeloma presenting with neutrophilia]
Momoko Yokoi1, Toshinori Kondo1, Risa Shimizu1
1Department of Hematology, Kawasaki Medical School.
Insights
G-CSF-producing myeloma is a rare condition where myeloma cells secrete granulocyte-colony stimulating factor (G-CSF), leading to neutrophilia. This case highlights successful treatment with daratumumab, lenalidomide, and dexamethasone, normalizing G-CSF levels and neutrophil counts.
Area of Science:
- Hematology
- Oncology
Background:
- Multiple myeloma is a plasma cell malignancy characterized by M proteinemia.
- Granulocyte-colony stimulating factor (G-CSF) is crucial for neutrophil production.
- G-CSF-producing myeloma is a rare subtype associated with neutrophilia.
Observation:
- A 71-year-old woman presented with nausea and anorexia, exhibiting neutrophilia and M proteinemia.
- Elevated serum G-CSF levels (160 pg/ml) and bone marrow plasmacytosis were noted.
- Immunohistochemistry confirmed G-CSF production by myeloma cells.
Findings:
- The patient was diagnosed with G-CSF-producing myeloma, with a negative CSF3R-T618I mutation.
- Treatment with daratumumab, lenalidomide, and dexamethasone achieved a very good partial response.
- Serum G-CSF levels and neutrophil counts normalized post-treatment.
Implications:
- G-CSF-producing myeloma requires specific diagnostic approaches, including serum G-CSF measurement and IHC.
- This case demonstrates the efficacy of novel therapies in managing this rare myeloma subtype.
- Further research is needed to understand the clinical characteristics and long-term prognosis of G-CSF-producing myeloma.
Abstract:
A 71-year-old woman complained of nausea and anorexia. Laboratory tests revealed significant neutrophilia and immunoglobulin A-kappa type M proteinemia, as well as increased plasma cells on bone marrow examination. Furthermore, the serum granulocyte-colony stimulating factor (G-CSF) concentration was high at 160 pg/ml, and the colony stimulating factor 3 receptor (CSF3R)-T618I mutation was negative. Immunohistochemical (IHC) analysis of bone marrow specimens using the anti-G-CSF antibody revealed immunopositivity of some myeloma cells. The patient was diagnosed using G-CSF-producing myeloma and was treated with daratumumab, lenalidomide, and dexamethasone. Her treatment resulted in a very good partial response, with normalization of both serum G-CSF levels and neutrophil count. There have been a few cases of G-CSF -producing myeloma reported, and it has previously been reported as chronic neutrophilic leukemia with M proteinemia. According to previous reports, techniques such as serum G-CSF measurements, IHC with an anti-G-CSF antibody, and CSF3R gene mutation analysis are useful for differentiating G-CSF-producing myeloma. However, the clinical characteristics and long-term prognosis of G-CSF-producing myeloma remain unknown. Additional case gathering and investigations are required.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Regulation of Hematopoietic Stem Cells

